Recent Updates — CDIX

Cardiff Lexington Corporation announced a letter of intent to acquire a multi-location musculoskeletal healthcare platform for up to $104 million. The consideration includes $30 million in cash, $10 million in unsecured notes, preferred equity granting sellers 35% post-closing ownership, and up to $12 million in common stock contingent on EBITDA targets of $15M, $18M, and $22M for 2027-2029. The transaction aims to expand the company's integrated regional healthcare operations combining orthopedics, spine care, and ancillary services. Closing is projected for November 16, 2026, subject to due diligence and financing. Cardiff Lexington Corporation operates as a healthcare holding company focused on acquiring and developing businesses in orthopedics, spine care, pain management, and related healthcare services.

Cardiff Lexington Corporation filed a Certificate of Designation on August 31, 2026, establishing Series A-1 preferred stock. The company designated two shares with a $250 stated value and liquidation preference. These shares rank senior to common stock but junior to several other existing series. Dividend rights are non-participatory with no economic interest in the company. Voting power equals 25% of all other equity votes plus one share, voting together with common stock. Transfers trigger automatic conversion into one common share, except for affiliate transfers. The company operates as a blank check company or special purpose acquisition vehicle.